B
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Bailu Peng investigates molecular mechanisms underlying multiple myeloma, a type of blood cancer. Research has focused on the role of specific genes and proteins in disease progression and immune response. One area of study examines how CST6 influences osteoclast differentiation, a process critical to bone destruction in multiple myeloma. Another line of research explores the potential of bispecific CAR-T cells, which target multiple antigens on cancer cells, as a therapeutic strategy. Additionally, Peng's work has identified NEK2, a gene highly expressed in myeloid progenitors, as a suppressor of T cell immunity in multiple myeloma and investigated NEK2 inhibition as a means to enhance the efficacy of PD-1/PD-L1 blockade therapies. Peng has published 29 papers, accumulating over 2,400 citations and an h-index of 17. Key collaborators at the University of Arkansas for Medical Sciences include Guido Tricot, John D. Shaughnessy Jr., Fumou Sun, and Frits van Rhee.
Metrics
- h-index: 17
- Publications: 29
- Citations: 2,467
Selected Publications
-
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023)
-
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation (2022)
-
NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma (2021)
-
Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma (2021)
Collaboration Network
Top Collaborators
Fumou Sun
Winthrop Rockefeller Foundation
4 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Yan Cheng
Winthrop Rockefeller Foundation (US)
4 shared publications
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Hongwei Xu
University of Arkansas for Medical Sciences (US)
4 shared publications
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Frits van Rhee
University of Arkansas for Medical Sciences
4 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Siegfried Janz
Medical College of Wisconsin (US)
3 shared publications
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Guido Tricot
Winthrop Rockefeller Foundation
3 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
John D. Shaughnessy
Winthrop Rockefeller Foundation
3 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Dongzheng Gai
University of Arkansas for Medical Sciences
3 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Fenghuang Zhan
Winthrop Rockefeller Foundation
2 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Huojun Cao
University of Iowa (US)
2 shared publications
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Jin‐Ran Chen
University of Arkansas for Medical Sciences
2 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Intawat Nookaew
University of Arkansas for Medical Sciences
2 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Cody Ashby
University of Arkansas for Medical Sciences
2 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Carolina Schinke
Winthrop Rockefeller Foundation
2 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Sharmilan Thanendrarajan
Winthrop Rockefeller Foundation
2 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Similar Researchers
Based on overlapping research topics
Fenghuang Zhan
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Behjatolah Monzavi Karbassi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Behjatolah Monzavi Karbassi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Guido Tricot
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Cody Ashby
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Immune Response and Inflammation